Last updated on February 2018

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment


Brief description of study

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

Detailed Study Description

This is a Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees of renal impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle 1) and the Extension Part (Cycles 2 and beyond). Patients may continue to receive treatment with TAS-102 during the study extension part only after completion of the Pharmacokinetic Part.

Clinical Study Identifier: NCT02301117

Contact Investigators or Research Sites near you

Start Over

Robert Winkler, MD

Sremska Kamenica Clinical Site
Sremska Kamenica, Serbia
  Connect »